1. Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group.
- Author
-
Spatz, Erica S, Gottlieb, Michael, Wisk, Lauren E, Anderson, Jill, Chang, Anna Marie, Gentile, Nicole L, Hill, Mandy J, Huebinger, Ryan M, Idris, Ahamed H, Kinsman, Jeremiah, Koo, Katherine, Li, Shu-Xia, McDonald, Samuel, Plumb, Ian D, Rodriguez, Robert M, Saydah, Sharon, Slovis, Benjamin, Stephens, Kari A, Unger, Elizabeth R, and Wang, Ralph C
- Subjects
- *
EVALUATION of medical care , *COVID-19 , *SARS-CoV-2 , *MYALGIA , *MILD cognitive impairment , *COMPARATIVE studies , *SURVEYS , *SLEEP disorders , *RESEARCH funding , *FATIGUE (Physiology) , *HEADACHE , *POST-infectious disorders , *LONGITUDINAL method , *CLINICAL trial registries , *SYMPTOMS , *ADULTS - Abstract
Background Long-term symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are a major concern, yet their prevalence is poorly understood. Methods We conducted a prospective cohort study comparing adults with SARS-CoV-2 infection (coronavirus disease-positive [COVID+]) with adults who tested negative (COVID−), enrolled within 28 days of a Food and Drug Administration (FDA)-approved SARS-CoV-2 test result for active symptoms. Sociodemographic characteristics, symptoms of SARS-CoV-2 infection (assessed with the Centers for Disease Control and Prevention [CDC] Person Under Investigation Symptom List), and symptoms of post-infectious syndromes (ie, fatigue, sleep quality, muscle/joint pains, unrefreshing sleep, and dizziness/fainting, assessed with CDC Short Symptom Screener for myalgic encephalomyelitis/chronic fatigue syndrome) were assessed at baseline and 3 months via electronic surveys sent via text or email. Results Among the first 1000 participants, 722 were COVID+ and 278 were COVID−. Mean age was 41.5 (SD 15.2); 66.3% were female, 13.4% were Black, and 15.3% were Hispanic. At baseline, SARS-CoV-2 symptoms were more common in the COVID+ group than the COVID− group. At 3 months, SARS-CoV-2 symptoms declined in both groups, although were more prevalent in the COVID+ group: upper respiratory symptoms/head/eyes/ears/nose/throat (HEENT; 37.3% vs 20.9%), constitutional (28.8% vs 19.4%), musculoskeletal (19.5% vs 14.7%), pulmonary (17.6% vs 12.2%), cardiovascular (10.0% vs 7.2%), and gastrointestinal (8.7% vs 8.3%); only 50.2% and 73.3% reported no symptoms at all. Symptoms of post-infectious syndromes were similarly prevalent among the COVID+ and COVID− groups at 3 months. Conclusions Approximately half of COVID+ participants, as compared with one-quarter of COVID− participants, had at least 1 SARS-CoV-2 symptom at 3 months, highlighting the need for future work to distinguish long COVID. Clinical Trials Registration NCT04610515. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF